Android Obesity

Definition and Fat Distribution Pattern

Android obesity (also called central, truncal, abdominal, or visceral obesity) is characterized by excess adipose tissue deposited predominantly in the upper body and abdominal region, giving a classic "apple shape." This contrasts with gynoid (peripheral) obesity, where fat accumulates in the hips, buttocks, and thighs ("pear shape").

After puberty, men tend to deposit fat intra-abdominally (android pattern)
Women more commonly store fat subcutaneously in the hips and thighs (gynoid pattern)
However, women with excess androgens or post-menopausal hormonal changes can also develop an android distribution
Basic Medical Biochemistry, 6e, p. 53

Measurement and Diagnostic Criteria

Several anthropometric tools are used to identify android obesity:

Measure	Android (High Risk) Threshold
Waist circumference (men)	> 40 in (102 cm)
Waist circumference (women)	> 35 in (89 cm)
Waist-to-hip ratio (men)	> 0.9
Waist-to-hip ratio (women)	> 0.85-0.8

Waist circumference is measured at the top of the iliac crest, or as the midpoint between the bottom of the 10th rib and the superior iliac crest at the midaxillary line. Waist-to-hip ratio is a simple, reliable indicator of visceral fat burden.

Textbook of Family Medicine, 9e
Current Surgical Therapy, 14e

Pathophysiology

Visceral Fat as an Endocrine Organ

Visceral fat (intraperitoneal adipose tissue) is not metabolically inert - it is a highly active endocrine organ that:

Releases free fatty acids directly into the portal circulation
Secretes pro-inflammatory cytokines (TNF-alpha, IL-6)
Drives a chronic low-grade inflammatory state
Produces adipokines that promote insulin resistance

Upper-body (android) fat deposition tends to occur by hypertrophy of existing fat cells, while lower-body (gynoid) fat grows by hyperplasia (formation of new cells). Hypertrophied visceral adipocytes are less sensitive to insulin and more lipolytically active, flooding the portal system with fatty acids.

Basic Medical Biochemistry, 6e
Current Surgical Therapy, 14e

Cardiovascular Pathophysiology

In android obesity, adipose tissue is located in the truncal region and is associated with:

Increased oxygen consumption (larger blood volume needed)
Left ventricular hypertrophy and eventual dysfunction
Increased stroke risk
Visceral fat is particularly linked to left ventricular dysfunction and CVD
Clinical Anesthesia (Barash), 9e

Metabolic Consequences and Comorbidities

Android/central obesity is strongly associated with a cluster of metabolic abnormalities:

Comorbidity	Mechanism
Insulin resistance / T2DM	Free fatty acids impair insulin signaling; adipokines antagonize insulin
Hypertension	Expanded blood volume; sympathetic activation; renin-angiotensin system upregulation
Dyslipidemia / Hyperlipidemia	Elevated portal FFA flux drives hepatic VLDL overproduction; raised TG, low HDL
Metabolic syndrome	Combination of the above with central obesity as a core criterion
Cardiovascular disease & stroke	Atherosclerosis driven by dyslipidemia, hypertension, inflammation
MASLD/NAFLD	Hepatic steatosis from excess portal FFA delivery
Gallbladder disease	Cholesterol supersaturation in bile
Breast and endometrial cancer	Excess estrogen production in visceral adipose tissue
Hyperinsulinemia	Compensatory response to insulin resistance

Basic Medical Biochemistry, 6e, p. 53
Current Surgical Therapy, 14e
Harrison's Principles of Internal Medicine, 22e

Android vs Gynoid Obesity: Key Differences

Feature	Android (Central)	Gynoid (Peripheral)
Shape	Apple	Pear
Fat location	Visceral/truncal	Hips, thighs, buttocks
More common in	Men; post-menopausal women	Pre-menopausal women
Waist-to-hip ratio	> 0.9 (M), > 0.85 (F)	< 0.9 (M), < 0.8 (F)
Metabolic activity	High (lipolytic, inflammatory)	Low
Insulin resistance risk	High	Low
CVD risk	High	Low
Fat cell mechanism	Hypertrophy	Hyperplasia

Clinical Significance

Populations with relatively low BMI but high visceral fat (e.g., South and East Asians) are at higher metabolic risk at BMI thresholds lower than the standard Western cutoffs. This highlights that distribution matters as much as total fat mass. A waist circumference > 35 in women or > 40 in men signals higher risk of metabolic syndrome regardless of BMI.

Android obesity is also associated with adiposopathy - a pathologic dysfunctional state of adipose tissue that worsens cardiometabolic outcomes. After determining the fat distribution pattern (android vs gynoid), biochemical workup is ordered to identify drivers: fasting glucose/HbA1c, fasting lipid panel, fasting insulin, TSH, CRP, and sometimes uric acid and liver enzymes.

Textbook of Family Medicine, 9e

Management Overview

Treatment targets both weight loss and reduction of visceral fat specifically:

Lifestyle modification - caloric restriction plus aerobic exercise (visceral fat responds particularly well to aerobic activity)
Pharmacotherapy (BMI ≥ 30, or ≥ 27 with comorbidities): options include GLP-1 receptor agonists (liraglutide, semaglutide), phentermine-topiramate, bupropion-naltrexone, orlistat
Bariatric surgery - for BMI ≥ 40 or ≥ 35 with serious comorbidities; substantially reduces visceral fat and reverses metabolic syndrome components
Treat underlying drivers: hyperandrogenism (PCOS), Cushing's syndrome, hypothyroidism

Clinical Anesthesia (Barash), 9e
Current Surgical Therapy, 14e

Summary: Android obesity is upper-body/visceral fat accumulation that drives a high-risk cardiometabolic phenotype through free fatty acid overload, chronic inflammation, and insulin resistance. Its identification by waist circumference and waist-to-hip ratio is a more sensitive predictor of metabolic risk than BMI alone.

This is a shared conversation. Sign in to Orris to start your own chat.